1		MEDICAL CANNABIS ACCESS AMENDMENTS
2		2022 GENERAL SESSION
3		STATE OF UTAH
4		Chief Sponsor: Luz Escamilla
5		House Sponsor:
6 7	LONG T	ITLE
8	General I	Description:
9	Th	is bill amends provisions regarding patient access and medical professionals in
10	relation to	medical cannabis.
11	Highlight	ed Provisions:
12	Th	is bill:
13	•	defines terms;
14	•	requires a hospice program to provide at least one qualified medical provider;
15	►	renames the Cannabinoid Product Board as the Cannabis Research Review Board
16	(board);	
17	•	requires physician members of the board to be qualified medical providers;
18	•	adds acute pain for which a medical professional may generally prescribe opioids as
19	a qualifyii	ng condition for a limited supply of medical cannabis;
20	•	amends provisions related to advertising regarding medical cannabis;
21	۲	requires a recommending medical provider to consider a patient's history of
22	substance	use or opioid use disorder before recommending medical cannabis;
23	•	amends provisions regarding the process to renew a medical cannabis card;
24	•	allows a designated caregiver facility to receive medical cannabis shipments on
25	behalf of a	a resident patient;
26	۲	allows a student's lawful dosage of medical cannabis on school grounds;
27	►	clarifies the enforcement authority of the Department of Health in relation to



licensed medical cannabis couriers;
 requires certain individuals overseeing certain higher education medical training to
be qualified medical providers; and
 makes technical and conforming changes.
Money Appropriated in this Bill:
None
Other Special Clauses:
This bill provides a special effective date.
Utah Code Sections Affected:
AMENDS:
26-21-2.1, as last amended by Laws of Utah 1997, Chapter 209
26-61-102, as enacted by Laws of Utah 2017, Chapter 398
26-61-201, as last amended by Laws of Utah 2018, Chapter 110
26-61a-102, as last amended by Laws of Utah 2021, Chapters 337 and 350
26-61a-104, as last amended by Laws of Utah 2020, Chapter 12
26-61a-105, as last amended by Laws of Utah 2021, Chapter 350
26-61a-106, as last amended by Laws of Utah 2021, Chapters 337 and 350
26-61a-201, as last amended by Laws of Utah 2021, Chapters 17, 337, and 350 and
further amended by Revisor Instructions, Laws of Utah 2021, Chapter 337
26-61a-202, as last amended by Laws of Utah 2021, Chapters 17, 337, and 350
26-61a-403, as last amended by Laws of Utah 2021, Chapters 337 and 350
26-61a-505, as last amended by Laws of Utah 2021, Chapter 350
26-61a-604, as last amended by Laws of Utah 2020, Chapter 354
26-61a-607, as last amended by Laws of Utah 2021, Chapter 350
26-61a-702, as last amended by Laws of Utah 2020, Chapter 354
ENACTS:
26-61a-116, Utah Code Annotated 1953
53B-17-903, Utah Code Annotated 1953

58 Section 1. Section **26-21-2.1** is amended to read:

59	26-21-2.1. Services.
60	(1) General acute hospitals and specialty hospitals shall remain open and be
61	continuously ready to receive patients 24 hours of every day in a year and have an attending
62	medical staff consisting of one or more physicians licensed to practice medicine and surgery
63	under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
64	Osteopathic Medical Practice Act.
65	(2) A specialty hospital shall provide on-site all basic services required of a general
66	acute hospital that are needed for the diagnosis, therapy, or rehabilitation offered to or required
67	by patients admitted to or cared for in the facility.
68	(3) (a) A home health agency shall provide at least licensed nursing services or
69	therapeutic services directly through the agency employees.
70	(b) A home health agency may provide additional services itself or under arrangements
71	with another agency, organization, facility, or individual.
72	(4) Beginning January 1, 2023, a hospice program shall provide at least one qualified
73	medical provider, as that term is defined in Section 26-61a-102, for the treatment of hospice
74	patients.
75	Section 2. Section 26-61-102 is amended to read:
76	26-61-102. Definitions.
77	As used in this chapter:
78	(1) "Approved study" means a medical research study:
79	(a) the purpose of which is to investigate the medical benefits and risks of cannabinoid
80	products; and
81	(b) that is approved by an IRB.
82	(2) "Board" means the [Cannabinoid Product] Cannabis Research Review Board
83	created in Section 26-61-201.
84	(3) "Cannabinoid product" means the same as that term is defined in Section 58-37-3.6.
85	(4) "Cannabis" means the same as that term is defined in Section 58-37-3.6.
86	(5) "Expanded cannabinoid product" means the same as that term is defined in Section
87	58-37-3.6.
88	(6) "Institutional review board" or "IRB" means an institutional review board that is
89	registered for human subject research by the United States Department of Health and Human

90	Services.
91	Section 3. Section 26-61-201 is amended to read:
92	26-61-201. Cannabis Research Review Board.
93	(1) There is created the [Cannabinoid Product] Cannabis Research Review Board
94	within the department.
95	(2) The department shall appoint, in consultation with a professional association based
96	in the state that represents physicians, seven members to the [Cannabinoid Product] Cannabis
97	Research Review Board as follows:
98	(a) three individuals who are medical research professionals; and
99	(b) four physicians who are qualified medical providers.
100	(3) The department shall ensure that at least one of the board members appointed under
101	Subsection (2) is a member of the Controlled Substances Advisory Committee created in
102	Section 58-38a-201.
103	(4) (a) Four of the board members appointed under Subsection (2) shall serve an initial
104	term of two years and three of the board members appointed under Subsection (2) shall serve
105	an initial term of four years.
106	(b) Successor board members shall each serve a term of four years.
107	(c) A board member appointed to fill a vacancy on the board shall serve the remainder
108	of the term of the board member whose departure created the vacancy.
109	(5) The department may remove a board member without cause.
110	(6) The board shall:
111	(a) nominate a board member to serve as chairperson of the board by a majority vote of
112	the board members[-]; and
113	[(7) The board shall] (b) meet as often as necessary to accomplish the duties assigned
114	to the board under this chapter.
115	[(8)] (7) Each board member, including the chair, has one vote.
116	[(9)] (a) A majority of board members constitutes a quorum.
117	(b) A vote of a majority of the quorum at any board meeting is necessary to take action
118	on behalf of the board.
119	[(10)] (9) A board member may not receive compensation for the member's service on
120	the board, but may, in accordance with rules adopted by the board in accordance with Title

121	63G, Chapter 3, Utah Administrative Rulemaking Act, receive:
122	(a) per diem at the rate established under Section $63A-3-106$; and
123	(b) travel expenses at the rate established under Section 63A-3-107.
124	(10) If a board member appointed under Subsection (2)(b) does not meet the
125	qualifications of Subsection (2)(b) before July 1, 2022:
126	(a) the board member's seat is vacant; and
127	(b) the department shall fill the vacancy in accordance with this section.
128	Section 4. Section 26-61a-102 is amended to read:
129	26-61a-102. Definitions.
130	As used in this chapter:
131	(1) "Active tetrahydrocannabinol" means Delta-8-THC, Delta-9-THC, and
132	tetrahydrocannabinolic acid.
133	(2) "[Cannabinoid Product] Cannabis Research Review Board" means the
134	[Cannabinoid Product] Cannabis Research Review Board created in Section 26-61-201.
135	(3) "Cannabis" means marijuana.
136	(4) "Cannabis cultivation facility" means the same as that term is defined in Section
137	4-41a-102.
138	(5) "Cannabis processing facility" means the same as that term is defined in Section
139	4-41a-102.
140	(6) "Cannabis product" means a product that:
141	(a) is intended for human use; and
142	(b) contains cannabis or tetrahydrocannabinol.
143	(7) "Cannabis production establishment" means the same as that term is defined in
144	Section 4-41a-102.
145	(8) "Cannabis production establishment agent" means the same as that term is defined
146	in Section 4-41a-102.
147	(9) "Cannabis production establishment agent registration card" means the same as that
148	term is defined in Section 4-41a-102.
149	(10) "Community location" means a public or private elementary or secondary school,
150	a church, a public library, a public playground, or a public park.
151	(11) "Conditional medical cannabis card" means an electronic medical cannabis card

- 152 that the department issues in accordance with Subsection 26-61a-201(1)(b) to allow an
- applicant for a medical cannabis card to access medical cannabis during the department's
- 154 review of the application.
- 155 (12) "Controlled substance database" means the controlled substance database created156 in Section 58-37f-201.
- 157 (13) "Delta-8-tetrahydrocannabinol" or "Delta-8-THC" means the cannabinoid that:
- 158 (a) is similar to Delta-9-THC with a lower psychotropic potency; and
- (b) interacts with the CB1 receptor of the nervous system.
- 160 (14) "Delta-9-tetrahydrocannabinol" or "Delta-9-THC" means the primary psychotropic161 cannabinoid in cannabis.
- 162 (15) "Department" means the Department of Health.
- 163 (16) "Designated caregiver" means:
- 164 (a) an individual:

182

- 165 (i) whom an individual with a medical cannabis patient card or a medical cannabis
- 166 guardian card designates as the patient's caregiver; and
- 167 (ii) who registers with the department under Section 26-61a-202; or
- (b) (i) a facility that an individual designates as a designated caregiver in accordance
 with Subsection 26-61a-202(1)(b); or
- 170 (ii) an assigned employee of the facility described in Subsection 26-61a-202(1)(b)(ii).
- 171 (17) "Directions of use" means recommended routes of administration for a medical172 cannabis treatment and suggested usage guidelines.
- (18) "Dosing guidelines" means a quantity range and frequency of administration for a
 recommended treatment of medical cannabis.
- (19) "Financial institution" means a bank, trust company, savings institution, or creditunion, chartered and supervised under state or federal law.
- (20) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy
 that the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
 shipments to a medical cannabis cardholder's home address to fulfill electronic orders that the
 state central patient portal facilitates.
- 181 (21) "Inventory control system" means the system described in Section 4-41a-103.
 - (22) "Legal dosage limit" means an amount that:

183	(a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the
184	relevant recommending medical provider or the state central patient portal or pharmacy
185	medical provider, in accordance with Subsection 26-61a-502(4) or (5), recommends; and
186	(b) may not exceed:
187	(i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and
188	(ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in total,
189	greater than 20 grams of active tetrahydrocannabinol.
190	(23) "Legal use termination date" means a date on the label of a container of
191	unprocessed cannabis flower:
192	(a) that is 60 days after the date of purchase of the cannabis; and
193	(b) after which, the cannabis is no longer in a medicinal dosage form outside of the
194	primary residence of the relevant medical cannabis patient cardholder.
195	(24) "Limited medical provider" means an individual who:
196	(a) meets the recommending qualifications; and
197	(b) has no more than 15 patients with a valid medical cannabis patient card or
198	provisional patient card as a result of the individual's recommendation, in accordance with
199	Subsection 26-61a-106(1)(b).
200	(25) "Marijuana" means the same as that term is defined in Section 58-37-2.
201	(26) "Medical cannabis" means cannabis in a medicinal dosage form or a cannabis
202	product in a medicinal dosage form.
203	(27) "Medical cannabis card" means a medical cannabis patient card, a medical
204	cannabis guardian card, a medical cannabis caregiver card, or a conditional medical cannabis
205	card.
206	(28) "Medical cannabis cardholder" means:
207	(a) a holder of a medical cannabis card; or
208	(b) a facility or assigned employee, described in Subsection (16)(b), only:
209	(i) within the scope of the facility's or assigned employee's performance of the role of a
210	medical cannabis patient cardholder's caregiver designation under Subsection
211	26-61a-202(1)(b); and
212	(ii) while in possession of documentation that establishes:
213	(A) a caregiver designation described in Subsection 26-61a-202(1)(b);

214 (B) the identity of the individual presenting the documentation; and 215 (C) the relation of the individual presenting the documentation to the caregiver 216 designation. 217 (29) "Medical cannabis caregiver card" means an electronic document that a cardholder 218 may print or store on an electronic device or a physical card or document that: 219 (a) the department issues to an individual whom a medical cannabis patient cardholder 220 or a medical cannabis guardian cardholder designates as a designated caregiver; and 221 (b) is connected to the electronic verification system. 222 (30) "Medical cannabis courier" means a courier that: 223 (a) the department licenses in accordance with Section 26-61a-604; and 224 (b) contracts with a home delivery medical cannabis pharmacy to deliver medical 225 cannabis shipments to fulfill electronic orders that the state central patient portal facilitates. 226 (31) "Medical cannabis courier agent" means an individual who: (a) is an employee of a medical cannabis courier; and 227 228 (b) who holds a valid medical cannabis courier agent registration card. 229 (32) (a) "Medical cannabis device" means a device that an individual uses to ingest or 230 inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form. (b) "Medical cannabis device" does not include a device that: 231 232 (i) facilitates cannabis combustion; or 233 (ii) an individual uses to ingest substances other than cannabis. 234 (33) "Medical cannabis guardian card" means an electronic document that a cardholder 235 may print or store on an electronic device or a physical card or document that: 236 (a) the department issues to the parent or legal guardian of a minor with a qualifying condition; and 237 238 (b) is connected to the electronic verification system. 239 (34) "Medical cannabis patient card" means an electronic document that a cardholder 240 may print or store on an electronic device or a physical card or document that: 241 (a) the department issues to an individual with a qualifying condition; and 242 (b) is connected to the electronic verification system. 243 (35) "Medical cannabis pharmacy" means a person that: 244 (a) (i) acquires or intends to acquire medical cannabis or a cannabis product in a

medicinal dosage form from a cannabis processing facility or another medical cannabis
pharmacy or a medical cannabis device; or
(ii) possesses medical cannabis or a medical cannabis device; and
(b) sells or intends to sell medical cannabis or a medical cannabis device to a medical
cannabis cardholder.
(36) "Medical cannabis pharmacy agent" means an individual who:
(a) is an employee of a medical cannabis pharmacy; and
(b) who holds a valid medical cannabis pharmacy agent registration card.
(37) "Medical cannabis pharmacy agent registration card" means a registration card
issued by the department that authorizes an individual to act as a medical cannabis pharmacy
agent.
(38) "Medical cannabis shipment" means a shipment of medical cannabis or a medical
cannabis product that a home delivery medical cannabis pharmacy or a medical cannabis
courier delivers to a medical cannabis cardholder's home address to fulfill an electronic medical
cannabis order that the state central patient portal facilitates.
(39) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a
cannabis product in a medicinal dosage form, or a medical cannabis device.
(40) (a) "Medicinal dosage form" means:
(i) for processed medical cannabis or a medical cannabis product, the following with a
specific and consistent cannabinoid content:
(A) a tablet;
(B) a capsule;
(C) a concentrated liquid or viscous oil;
(D) a liquid suspension;
(E) a topical preparation;
(F) a transdermal preparation;
(G) a sublingual preparation;
(H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or
rectangular cuboid shape; or
(I) a resin or wax;
(ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:

276	(A) contains cannabis flowers in a quantity that varies by no more than 10% from the
277	stated weight at the time of packaging;
278	(B) at any time the medical cannabis cardholder transports or possesses the container in
279	public, is contained within an opaque bag or box that the medical cannabis pharmacy provides;
280	and
281	(C) is labeled with the container's content and weight, the date of purchase, the legal use
282	termination date, and after December 31, 2020, a barcode that provides information connected
283	to an inventory control system; and
284	(iii) a form measured in grams, milligrams, or milliliters.
285	(b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:
286	(i) the medical cannabis cardholder has recently removed from the container described
287	in Subsection (40)(a)(ii) for use; and
288	(ii) does not exceed the quantity described in Subsection (40)(a)(ii).
289	(c) "Medicinal dosage form" does not include:
290	(i) any unprocessed cannabis flower outside of the container described in Subsection
291	(40)(a)(ii), except as provided in Subsection (40)(b);
292	(ii) any unprocessed cannabis flower in a container described in Subsection (40)(a)(ii)
293	after the legal use termination date; or
294	(iii) a process of vaporizing and inhaling concentrated cannabis by placing the cannabis
295	on a nail or other metal object that is heated by a flame, including a blowtorch.
296	(41) "Nonresident patient" means an individual who:
297	(a) is not a resident of Utah or has been a resident of Utah for less than 45 days;
298	(b) has a currently valid medical cannabis card or the equivalent of a medical cannabis
299	card under the laws of another state, district, territory, commonwealth, or insular possession of
300	the United States; and
301	(c) has been diagnosed with a qualifying condition as described in Section 26-61a-104.
302	(42) "Payment provider" means an entity that contracts with a cannabis production
303	establishment or medical cannabis pharmacy to facilitate transfers of funds between the
304	establishment or pharmacy and other businesses or individuals.
305	(43) "Pharmacy medical provider" means the medical provider required to be on site at
306	a medical cannabis pharmacy under Section 26-61a-403.

307	(44) "Provisional patient card" means a card that:
308	(a) the department issues to a minor with a qualifying condition for whom:
309	(i) a recommending medical provider has recommended a medical cannabis treatment;
310	and
311	(ii) the department issues a medical cannabis guardian card to the minor's parent or
312	legal guardian; and
313	(b) is connected to the electronic verification system.
314	(45) "Qualified medical provider" means an individual:
315	(a) who meets the recommending qualifications; and
316	(b) whom the department registers to recommend treatment with cannabis in a
317	medicinal dosage form under Section 26-61a-106.
318	(46) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section
319	26-61a-109.
320	(47) "Qualifying condition" means a condition described in Section 26-61a-104.
321	(48) "Recommend" or "recommendation" means, for a recommending medical
322	provider, the act of suggesting the use of medical cannabis treatment, which:
323	(a) certifies the patient's eligibility for a medical cannabis card; and
324	(b) may include, at the recommending medical provider's discretion, directions of use,
325	with or without dosing guidelines.
326	(49) "Recommending medical provider" means a qualified medical provider or a
327	limited medical provider.
328	(50) "Recommending qualifications" means that an individual:
329	(a) (i) has the authority to write a prescription;
330	(ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah
331	Controlled Substances Act; and
332	(iii) possesses the authority, in accordance with the individual's scope of practice, to
333	prescribe a Schedule II controlled substance; and
334	(b) is licensed as:
335	(i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
336	(ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice
337	Act;

338	(iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,
339	Chapter 68, Utah Osteopathic Medical Practice Act; or
340	(iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.
341	(51) "State central patient portal" means the website the department creates, in
342	accordance with Section 26-61a-601, to facilitate patient safety, education, and an electronic
343	medical cannabis order.
344	(52) "State central patient portal medical provider" means a physician or pharmacist
345	that the department employs in relation to the state central patient portal to consult with
346	medical cannabis cardholders in accordance with Section 26-61a-602.
347	(53) "State electronic verification system" means the system described in Section
348	26-61a-103.
349	(54) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a
350	synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).
351	(55) "Valid form of photo identification" means any of the following forms of
352	identification that is either current or has expired within the previous six months:
353	(a) a valid state-issued driver license or identification card;
354	(b) a valid United States federal-issued photo identification, including:
355	(i) a United States passport;
356	(ii) a United States passport card;
357	(iii) a United States military identification card; or
358	(iv) a permanent resident card or alien registration receipt card; or
359	(c) a passport that another country issued.
360	Section 5. Section 26-61a-104 is amended to read:
361	26-61a-104. Qualifying condition.
362	(1) By designating a particular condition under Subsection (2) for which the use of
363	medical cannabis to treat symptoms is decriminalized, the Legislature does not conclusively
364	state that:
365	(a) current scientific evidence clearly supports the efficacy of a medical cannabis
366	treatment for the condition; or
367	(b) a medical cannabis treatment will treat, cure, or positively affect the condition.
368	(2) For the purposes of this chapter, each of the following conditions is a qualifying

369	condition:
370	(a) HIV or acquired immune deficiency syndrome;
371	(b) Alzheimer's disease;
372	(c) amyotrophic lateral sclerosis;
373	(d) cancer;
374	(e) cachexia;
375	(f) persistent nausea that is not significantly responsive to traditional treatment, except
376	for nausea related to:
377	(i) pregnancy;
378	(ii) cannabis-induced cyclical vomiting syndrome; or
379	(iii) cannabinoid hyperemesis syndrome;
380	(g) Crohn's disease or ulcerative colitis;
381	(h) epilepsy or debilitating seizures;
382	(i) multiple sclerosis or persistent and debilitating muscle spasms;
383	(j) post-traumatic stress disorder that is being treated and monitored by a licensed
384	mental health therapist, as that term is defined in Section 58-60-102, and that:
385	(i) has been diagnosed by a healthcare provider or mental health provider employed or
386	contracted by the United States Veterans Administration, evidenced by copies of medical
387	records from the United States Veterans Administration that are included as part of the
388	qualified medical provider's pre-treatment assessment and medical record documentation; or
389	(ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of
390	the patient, by a provider who is:
391	(A) a licensed board-eligible or board-certified psychiatrist;
392	(B) a licensed psychologist with a master's-level degree;
393	(C) a licensed clinical social worker with a master's-level degree; or
394	(D) a licensed advanced practice registered nurse who is qualified to practice within
395	the psychiatric mental health nursing [speciality] specialty and who has completed the clinical
396	practice requirements in psychiatric mental health nursing, including in psychotherapy, in
397	accordance with Subsection 58-31b-302(4)(g);
398	(k) autism;
399	(1) a terminal illness when the patient's remaining life expectancy is less than six

400	months;
401	(m) a condition resulting in the individual receiving hospice care;
402	(n) a rare condition or disease that:
403	(i) affects less than 200,000 individuals in the United States, as defined in Section 526
404	of the Federal Food, Drug, and Cosmetic Act; and
405	(ii) is not adequately managed despite treatment attempts using:
406	(A) conventional medications other than opioids or opiates; or
407	(B) physical interventions;
408	(o) pain lasting longer than two weeks that is not adequately managed, in the qualified
409	medical provider's opinion, despite treatment attempts using:
410	(i) conventional medications other than opioids or opiates; or
411	(ii) physical interventions; [and]
412	(p) pain that is expected to last for two weeks or longer for an acute condition,
413	including a surgical procedure, for which a medical professional may generally prescribe
414	opioids for a limited duration, subject to Subsection 26-61a-201(5)(c); and
415	$\left[\frac{(p)}{(q)}\right]$ a condition that the Compassionate Use Board approves under Section
416	26-61a-105, on an individual, case-by-case basis.
417	Section 6. Section 26-61a-105 is amended to read:
418	26-61a-105. Compassionate Use Board.
419	(1) (a) The department shall establish a Compassionate Use Board consisting of:
420	(i) seven qualified medical providers that the executive director appoints and the
421	Senate confirms:
422	(A) who are knowledgeable about the medicinal use of cannabis;
423	(B) who are physicians licensed under Title 58, Chapter 67, Utah Medical Practice Act,
424	or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and
425	(C) whom the appropriate board certifies in the specialty of neurology, pain medicine
426	and pain management, medical oncology, psychiatry, infectious disease, internal medicine,
427	pediatrics, or gastroenterology; and
428	(ii) as a nonvoting member and the chair of the Compassionate Use Board, the
429	executive director or the director's designee.
430	(b) In appointing the seven qualified medical providers described in Subsection (1)(a),

- the executive director shall ensure that at least two have a board certification in pediatrics.
 (2) (a) Of the members of the Compassionate Use Board that the executive director
- 432 (2) (a) Of the memoers of the compassionate Use Board that the executive director 433 first appoints:
- 434 (i) three shall serve an initial term of two years; and 435 (ii) the remaining members shall serve an initial term of four years. 436 (b) After an initial term described in Subsection (2)(a) expires: 437 (i) each term is four years; and 438 (ii) each board member is eligible for reappointment. 439 (c) A member of the Compassionate Use Board may serve until a successor is 440 appointed. 441 (3) Four members constitute a quorum of the Compassionate Use Board. 442 (4) A member of the Compassionate Use Board may receive: 443 (a) notwithstanding Section 63A-3-106, compensation or benefits for the member's 444 service; and 445 (b) travel expenses in accordance with Section 63A-3-107 and rules made by the 446 Division of Finance in accordance with Section 63A-3-107. 447 (5) The Compassionate Use Board shall: 448 (a) review and recommend for department approval a petition to the board regarding an 449 individual described in Subsection 26-61a-201(2)(a), a minor described in Subsection 450 26-61a-201(2)(c), or an individual who is not otherwise qualified to receive a medical cannabis 451 card to obtain a medical cannabis card for compassionate use, for the standard or a reduced 452 period of validity, if: 453 (i) for an individual who is not otherwise qualified to receive a medical cannabis card, 454 the individual's qualified medical provider is actively treating the individual for an intractable 455 condition that: (A) substantially impairs the individual's quality of life: and 456 457 (B) has not, in the qualified medical provider's professional opinion, adequately 458 responded to conventional treatments;
 - 459 (ii) the qualified medical provider:
 - 460 (A) recommends that the individual or minor be allowed to use medical cannabis; and
 - 461 (B) provides a letter, relevant treatment history, and notes or copies of progress notes

462 describing relevant treatment history including rationale for considering the use of medical 463 cannabis; and 464 (iii) the Compassionate Use Board determines that: 465 (A) the recommendation of the individual's qualified medical provider is justified; and 466 (B) based on available information, it may be in the best interests of the individual to 467 allow the use of medical cannabis; 468 (b) review and approve or deny the use of a medical cannabis device for an individual 469 described in Subsection 26-61a-201(2)(a)(i)(B) or a minor described in Subsection 470 26-61a-201(2)(c) if the individual's or minor's qualified medical provider recommends that the 471 individual or minor be allowed to use a medical cannabis device to vaporize the medical 472 cannabis treatment; 473 (c) unless no petitions are pending: 474 (i) meet to receive or review compassionate use petitions at least quarterly; and 475 (ii) if there are more petitions than the board can receive or review during the board's 476 regular schedule, as often as necessary; 477 (d) except as provided in Subsection (6), complete a review of each petition and 478 recommend to the department approval or denial of the applicant for qualification for a medical 479 cannabis card within 90 days after the day on which the board received the petition: 480 (e) consult with the department regarding the criteria described in Subsection (6); and 481 (f) report, before November 1 of each year, to the Health and Human Services Interim 482 Committee: 483 (i) the number of compassionate use recommendations the board issued during the past 484 year; and 485 (ii) the types of conditions for which the board recommended compassionate use. 486 (6) The department shall make rules, in consultation with the Compassionate Use 487 Board and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to 488 establish a process and criteria for a petition to the board to automatically qualify for expedited 489 final review and approval or denial by the department in cases where, in the determination of 490 the department and the board: 491 (a) time is of the essence; 492 (b) engaging the full review process would be unreasonable in light of the petitioner's

493	physical condition; and
494	(c) sufficient factors are present regarding the petitioner's safety.
495	(7) (a) (i) The department shall review:
496	(A) any compassionate use for which the Compassionate Use Board recommends
497	approval under Subsection (5)(d) to determine whether the board properly exercised the board's
498	discretion under this section; and
499	(B) any expedited petitions the department receives under the process described in
500	Subsection (6).
501	(ii) If the department determines that the Compassionate Use Board properly exercised
502	the board's discretion in recommending approval under Subsection (5)(d) or that the expedited
503	petition merits approval based on the criteria established in accordance with Subsection (6), the
504	department shall:
505	(A) issue the relevant medical cannabis card; and
506	(B) provide for the renewal of the medical cannabis card in accordance with the
507	recommendation of the qualified medical provider described in Subsection (5)(a).
508	(b) (i) If the Compassionate Use Board recommends denial under Subsection (5)(d),
509	the individual seeking to obtain a medical cannabis card may petition the department to review
510	the board's decision.
511	(ii) If the department determines that the Compassionate Use Board's recommendation
512	for denial under Subsection (5)(d) was arbitrary or capricious:
513	(A) the department shall notify the Compassionate Use Board of the department's
514	determination; and
515	(B) the board shall reconsider the Compassionate Use Board's refusal to recommend
516	approval under this section.
517	(c) In reviewing the Compassionate Use Board's recommendation for approval or
518	denial under Subsection (5)(d) in accordance with this Subsection (7), the department shall
519	presume the board properly exercised the board's discretion unless the department determines
520	that the board's recommendation was arbitrary or capricious.
521	(8) Any individually identifiable health information contained in a petition that the
522	Compassionate Use Board or department receives under this section is a protected record in
523	accordance with Title 63G, Chapter 2, Government Records Access and Management Act.

524 (9) The Compassionate Use Board shall annually report the board's activity to the 525 [Cannabinoid Product] Cannabis Research Review Board. 526 Section 7. Section **26-61a-106** is amended to read: 527 26-61a-106. Qualified medical provider registration -- Continuing education --528 Treatment recommendation -- Limited medical provider. 529 (1) (a) (i) Except as provided in Subsection (1)(b), an individual may not recommend a 530 medical cannabis treatment unless the department registers the individual as a qualified 531 medical provider in accordance with this section. 532 (ii) Notwithstanding Subsection (1)(a)(i), a qualified medical provider who is podiatrist 533 licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act, may not recommend a 534 medical cannabis treatment except within the course and scope of a practice of podiatry, as that 535 term is defined in Section 58-5a-102. 536 (b) Beginning on the earlier of September 1, 2021, or the date on which the department gives notice that the electronic verification system is functionally capable as described in 537 538 Subsection 26-61a-103(2)(d), an individual who meets the recommending qualifications may recommend a medical cannabis treatment as a limited medical provider without registering 539 540 under Subsection (1)(a) if: 541 (i) the individual recommends the use of medical cannabis to the patient through an 542 order described in Subsection (1)(c) after: (A) a face-to-face visit for an initial recommendation or the renewal of a 543 544 recommendation for a patient for whom the limited medical provider did not make the patient's 545 original recommendation; or 546 (B) a visit using telehealth services for a renewal of a recommendation for a patient for whom the limited medical provider made the patient's original recommendation; and 547 548 (ii) the individual's recommendation or renewal would not cause the total number of 549 the individual's patients who have a valid medical cannabis patient card or provisional patient 550 card resulting from the individual's recommendation to exceed 15. (c) The individual described in Subsection (1)(b) shall communicate the individual's 551 552 recommendation through an order for the medical cannabis pharmacy to record the individual's 553 recommendation or renewal in the state electronic verification system under the individual's 554 recommendation that:

555	(i) (A) that the individual or the individual's employee sends electronically to a medical
556	cannabis pharmacy; or
557	(B) that the individual gives to the patient in writing for the patient to deliver to a
558	medical cannabis pharmacy; and
559	(ii) may include:
560	(A) directions of use or dosing guidelines; and
561	(B) an indication of a need for a caregiver in accordance with Subsection
562	26-61a-201(3)(c).
563	(d) If the limited medical provider gives the patient a written recommendation to
564	deliver to a medical cannabis pharmacy under Subsection (1)(c)(i)(B), the limited medical
565	provider shall ensure that the document includes all of the information that is included on a
566	prescription the provider would issue for a controlled substance, including:
567	(i) the date of issuance;
568	(ii) the provider's name, address and contact information, controlled substance license
569	information, and signature; and
570	(iii) the patient's name, address and contact information, age, and diagnosed qualifying
571	condition.
572	(e) In considering making a recommendation as a limited medical provider, an
573	individual may consult information that the department makes available on the department's
574	website for recommending providers.
575	(2) (a) The department shall, within 15 days after the day on which the department
576	receives an application from an individual, register and issue a qualified medical provider
577	registration card to the individual if the individual:
578	(i) provides to the department the individual's name and address;
579	(ii) provides to the department a report detailing the individual's completion of the
580	applicable continuing education requirement described in Subsection (3);
581	(iii) provides to the department evidence that the individual meets the recommending
582	qualifications;
583	(iv) for an applicant on or after November 1, 2021, provides to the department the
584	information described in Subsection (10)(a); and
585	(v) pays the department a fee in an amount that:

(ii) an owner, officer, director, board member, employee, or agent of a cannabisproduction establishment, a medical cannabis pharmacy, or a medical cannabis courier.

(A) the department sets, in accordance with Section 63J-1-504; and

(b) The department may not register an individual as a qualified medical provider if the

(B) does not exceed \$300 for an initial registration.

593 (3) (a) An individual shall complete the continuing education described in this594 Subsection (3) in the following amounts:

- 595 (i) for an individual as a condition precedent to registration, four hours; and
- (ii) for a qualified medical provider as a condition precedent to renewal, four hoursevery two years.
- 598 (b) In accordance with Subsection (3)(a), a qualified medical provider shall:
- 599 (i) complete continuing education:
- 600 (A) regarding the topics described in Subsection (3)(d); and
- (B) offered by the department under Subsection (3)(c) or an accredited or approved
 continuing education provider that the department recognizes as offering continuing education
 appropriate for the recommendation of cannabis to patients; and
- (ii) make a continuing education report to the department in accordance with a process
 that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah
 Administrative Rulemaking Act, and in collaboration with the Division of Occupational and
 Professional Licensing and:
- 608 (A) for a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing
 609 Act, the Podiatric Physician Board;
- 610 (B) for an advanced practice registered nurse licensed under Title 58, Chapter 31b,
 611 Nurse Practice Act, the Board of Nursing;
- 612 (C) for a qualified medical provider licensed under Title 58, Chapter 67, Utah Medical
 613 Practice Act, the Physicians Licensing Board;
- 614 (D) for a qualified medical provider licensed under Title 58, Chapter 68, Utah
 615 Osteopathic Medical Practice Act, the Osteopathic Physician and Surgeon's Licensing Board;
 616 and

individual is:


586 587

588

589

590

617 (E) for a physician assistant licensed under Title 58, Chapter 70a, Utah Physician 618 Assistant Act, the Physician Assistant Licensing Board. 619 (c) The department may, in consultation with the Division of Occupational and 620 Professional Licensing, develop the continuing education described in this Subsection (3). 621 (d) The continuing education described in this Subsection (3) may discuss: 622 (i) the provisions of this chapter; 623 (ii) general information about medical cannabis under federal and state law; 624 (iii) the latest scientific research on the endocannabinoid system and medical cannabis. 625 including risks and benefits; 626 (iv) recommendations for medical cannabis as it relates to the continuing care of a 627 patient in pain management, risk management, potential addiction, or palliative care; and 628 (v) best practices for recommending the form and dosage of medical cannabis products 629 based on the qualifying condition underlying a medical cannabis recommendation. (4) (a) Except as provided in Subsection (4)(b), a qualified medical provider may not 630 631 recommend a medical cannabis treatment to more than 275 of the qualified medical provider's 632 patients at the same time, as determined by the number of medical cannabis cards under the 633 qualified medical provider's name in the state electronic verification system. 634 (b) A gualified medical provider may recommend a medical cannabis treatment to up to 635 600 of the qualified medical provider's patients at any given time, as determined by the number 636 of medical cannabis cards under the qualified medical provider's name in the state electronic 637 verification system, if: 638 (i) the appropriate American medical board has certified the qualified medical provider 639 in the specialty of anesthesiology, gastroenterology, neurology, oncology, pain, hospice and 640 palliative medicine, physical medicine and rehabilitation, rheumatology, endocrinology, or 641 psychiatry; or 642 (ii) a licensed business employs or contracts with the qualified medical provider for the 643 specific purpose of providing hospice and palliative care. 644 (5) A recommending medical provider may recommend medical cannabis to an 645 individual under this chapter only in the course of a provider-patient relationship after the 646 recommending medical provider has completed and documented in the patient's medical record 647 a thorough assessment of the patient's condition and medical history based on the appropriate



679	(b) a medical cannabis pharmacy or an owner, officer, director, board member,
680	employee, or agent of a medical cannabis pharmacy; or
681	(c) a recommending medical provider or pharmacy medical provider.
682	(10) (a) On or before November 1, 2021, a qualified medical provider shall report to
683	the department, in a manner designated by the department:
684	(i) if applicable, that the qualified medical provider or the entity that employs the
685	qualified medical provider represents online or on printed material that the qualified medical
686	provider is a qualified medical provider or offers medical cannabis recommendations to
687	patients; and
688	(ii) the fee amount that the qualified medical provider or the entity that employs the
689	qualified medical provider charges a patient for a medical cannabis recommendation, either as
690	an actual cash rate or, if the provider or entity bills insurance, an average cash rate.
691	(b) The department shall:
692	(i) ensure that the following information related to qualified medical providers and
693	entities described in Subsection (10)(a)(i) is available on the department's website or on the
694	health care price transparency tool under Subsection (10)(b)(ii):
695	(A) the name of the qualified medical provider and, if applicable, the name of the
696	entity that employs the qualified medical provider;
697	(B) the address of the qualified medical provider's office or, if applicable, the entity
698	that employs the qualified medical provider; and
699	(C) the fee amount described in Subsection (10)(a)(ii); and
700	(ii) share data collected under this Subsection (10) with the state auditor for use in the
701	health care price transparency tool described in Section 67-3-11.
702	Section 8. Section 26-61a-116 is enacted to read:
703	<u>26-61a-116.</u> Advertising.
704	(1) Except as provided in this chapter, a person may not advertise regarding the
705	recommendation, sale, dispensing, or transportation of medical cannabis.
706	(2) Notwithstanding any authorization to advertise regarding medical cannabis under
707	this chapter, the person advertising may not advertise:
708	(a) using promotional discounts or incentives;
709	(b) except as provided in Section 26-61a-403, a particular medical cannabis product,

710	medical cannabis device, or medicinal dosage form; or
711	(c) an assurance regarding an outcome related to medical cannabis treatment.
712	(3) The department shall define standards for advertising authorized under this chapter,
713	including names and logos, to ensure a medical rather than recreational disposition.
714	Section 9. Section 26-61a-201 is amended to read:
715	26-61a-201. Medical cannabis patient card Medical cannabis guardian card
716	Conditional medical cannabis card Application Fees Studies.
717	(1) (a) The department shall, within 15 days after the day on which an individual who
718	satisfies the eligibility criteria in this section or Section 26-61a-202 submits an application in
719	accordance with this section or Section 26-61a-202:
720	(i) issue a medical cannabis patient card to an individual described in Subsection
721	(2)(a);
722	(ii) issue a medical cannabis guardian card to an individual described in Subsection
723	(2)(b);
724	(iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
725	(iv) issue a medical cannabis caregiver card to an individual described in Subsection
726	26-61a-202(4).
727	(b) (i) Beginning on the earlier of September 1, 2021, or the date on which the
728	electronic verification system is functionally capable of facilitating a conditional medical
729	cannabis card under this Subsection (1)(b), upon the entry of a recommending medical
730	provider's medical cannabis recommendation for a patient in the state electronic verification
731	system, either by the provider or the provider's employee or by a medical cannabis pharmacy
732	medical provider or medical cannabis pharmacy in accordance with Subsection
733	26-61a-501(11)(a), the department shall issue to the patient an electronic conditional medical
734	cannabis card, in accordance with this Subsection (1)(b).
735	(ii) A conditional medical cannabis card is valid for the lesser of:
736	(A) 60 days; or
737	(B) the day on which the department completes the department's review and issues a
738	medical cannabis card under Subsection (1)(a), denies the patient's medical cannabis card
739	application, or revokes the conditional medical cannabis card under Subsection (8).
740	(iii) The department may issue a conditional medical cannabis card to an individual

741	applying for a medical cannabis patient card for which approval of the Compassionate Use
742	Board is not required.
743	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
744	obligations under law applicable to a holder of the medical cannabis card for which the
745	individual applies and for which the department issues the conditional medical cannabis card.
746	(2) (a) An individual is eligible for a medical cannabis patient card if:
747	(i) (A) the individual is at least 21 years old; or
748	(B) the individual is 18, 19, or 20 years old, the individual petitions the Compassionate
749	Use Board under Section 26-61a-105, and the Compassionate Use Board recommends
750	department approval of the petition;
751	(ii) the individual is a Utah resident;
752	(iii) the individual's recommending medical provider recommends treatment with
753	medical cannabis in accordance with Subsection (4);
754	(iv) the individual signs an acknowledgment stating that the individual received the
755	information described in Subsection (8); and
756	(v) the individual pays to the department a fee in an amount that, subject to Subsection
757	26-61a-109(5), the department sets in accordance with Section 63J-1-504.
758	(b) (i) An individual is eligible for a medical cannabis guardian card if the individual:
759	(A) is at least 18 years old;
760	(B) is a Utah resident;
761	(C) is the parent or legal guardian of a minor for whom the minor's qualified medical
762	provider recommends a medical cannabis treatment, the individual petitions the Compassionate
763	Use Board under Section 26-61a-105, and the Compassionate Use Board recommends
764	department approval of the petition;
765	(D) the individual signs an acknowledgment stating that the individual received the
766	information described in Subsection (9);
767	(E) pays to the department a fee in an amount that, subject to Subsection
768	26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the
769	criminal background check described in Section 26-61a-203; and
770	(F) the individual has not been convicted of a misdemeanor or felony drug distribution
771	offense under either state or federal law, unless the individual completed any imposed sentence

772 six months or more before the day on which the individual applies for a medical cannabis 773 guardian card. 774 (ii) The department shall notify the Department of Public Safety of each individual that 775 the department registers for a medical cannabis guardian card. 776 (c) (i) A minor is eligible for a provisional patient card if: 777 (A) the minor has a qualifying condition; 778 (B) the minor's qualified medical provider recommends a medical cannabis treatment 779 to address the minor's qualifying condition: 780 (C) one of the minor's parents or legal guardians petitions the Compassionate Use 781 Board under Section 26-61a-105, and the Compassionate Use Board recommends department 782 approval of the petition; and 783 (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card 784 under Subsection (2)(b) or designates a caregiver under Subsection (2)(d) who is eligible for a medical cannabis caregiver card under Section 26-61a-202. 785 786 (ii) The department shall automatically issue a provisional patient card to the minor 787 described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis 788 guardian card to the minor's parent or legal guardian. 789 (d) Beginning on the earlier of September 1, 2021, or the date on which the electronic 790 verification system is functionally capable of servicing the designation, if the parent or legal 791 guardian of a minor described in Subsections (2)(c)(i)(A) through (C) does not qualify for a 792 medical cannabis guardian card under Subsection (2)(b), the parent or legal guardian may 793 designate up to two caregivers in accordance with Subsection 26-61a-202(1)(c) to ensure that 794 the minor has adequate and safe access to the recommended medical cannabis treatment. 795 (3) (a) An individual who is eligible for a medical cannabis card described in 796 Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the 797 department: 798 (i) through an electronic application connected to the state electronic verification 799 system; 800 (ii) with the recommending medical provider; and 801 (iii) with information including: 802 (A) the applicant's name, gender, age, and address;

803	(B) the number of the applicant's valid form of photo identification;
804	(C) for a medical cannabis guardian card, the name, gender, and age of the minor
805	receiving a medical cannabis treatment under the cardholder's medical cannabis guardian card;
806	and
807	(D) for a provisional patient card, the name of the minor's parent or legal guardian who
808	holds the associated medical cannabis guardian card.
809	(b) The department shall ensure that a medical cannabis card the department issues
810	under this section contains the information described in Subsection (3)(a)(iii).
811	(c) (i) If a recommending medical provider determines that, because of age, illness, or
812	disability, a medical cannabis patient cardholder requires assistance in administering the
813	medical cannabis treatment that the recommending medical provider recommends, the
814	recommending medical provider may indicate the cardholder's need in the state electronic
815	verification system, either directly or, for a limited medical provider, through the order
816	described in Subsections 26-61a-106(1)(c) and (d).
817	(ii) If a recommending medical provider makes the indication described in Subsection
818	(3)(c)(i):
819	(A) the department shall add a label to the relevant medical cannabis patient card
820	indicating the cardholder's need for assistance;
821	(B) any adult who is 18 years old or older and who is physically present with the
822	cardholder at the time the cardholder needs to use the recommended medical cannabis
823	treatment may handle the medical cannabis treatment and any associated medical cannabis
824	device as needed to assist the cardholder in administering the recommended medical cannabis
825	treatment; and
826	(C) an individual of any age who is physically present with the cardholder in the event
827	of an emergency medical condition, as that term is defined in Section 31A-22-627, may handle
828	the medical cannabis treatment and any associated medical cannabis device as needed to assist
829	the cardholder in administering the recommended medical cannabis treatment.
830	(iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may not:
831	(A) ingest or inhale medical cannabis;
832	(B) possess, transport, or handle medical cannabis or a medical cannabis device outside
833	of the immediate area where the cardholder is present or with an intent other than to provide

834	assistance to the cardholder; or
835	(C) possess, transport, or handle medical cannabis or a medical cannabis device when
836	the cardholder is not in the process of being dosed with medical cannabis.
837	(4) To recommend a medical cannabis treatment to a patient or to renew a
838	recommendation, a recommending medical provider shall:
839	(a) before recommending or renewing a recommendation for medical cannabis in a
840	medicinal dosage form or a cannabis product in a medicinal dosage form:
841	(i) verify the patient's and, for a minor patient, the minor patient's parent or legal
842	guardian's valid form of identification described in Subsection (3)(a);
843	(ii) review any record related to the patient and, for a minor patient, the patient's parent
844	or legal guardian in:
845	(A) for a qualified medical provider, the state electronic verification system; and
846	(B) the controlled substance database created in Section 58-37f-201; and
847	(iii) consider the recommendation in light of the patient's qualifying condition, history
848	of substance use or opioid use disorder, and history of medical cannabis and controlled
849	substance use during an initial face-to-face visit with the patient; and
850	(b) state in the recommending medical provider's recommendation that the patient:
851	(i) suffers from a qualifying condition, including the type of qualifying condition; and
852	(ii) may benefit from treatment with cannabis in a medicinal dosage form or a cannabis
853	product in a medicinal dosage form.
854	(5) (a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the
855	department issues under this section is valid for the lesser of:
856	(i) an amount of time that the recommending medical provider determines; or
857	(ii) (A) six months for the first issuance, and, except as provided in Subsection
858	(5)(a)(ii)(B), for a renewal; or
859	(B) for a renewal, one year if, after at least one year following the issuance of the
860	original medical cannabis card, the recommending medical provider determines that the patient
861	has been stabilized on the medical cannabis treatment and a one-year renewal period is
862	justified.
863	(b) (i) A medical cannabis card that the department issues in relation to a terminal
864	illness described in Section 26-61a-104 does not expire.

865	(ii) The recommending medical provider may revoke a recommendation that the
866	provider made in relation to a terminal illness described in Section 26-61a-104 if the medical
867	cannabis cardholder no longer has the terminal illness.
868	(c) A medical cannabis card that the department issues in relation to acute pain as
869	described in Section 26-61a-104 expires 30 days after the day on which the department first
870	issues a conditional or full medical cannabis card.
871	(6) (a) A medical cannabis patient card or a medical cannabis guardian card is
872	renewable if:
873	(i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or
874	(b); or
875	(ii) the cardholder received the medical cannabis card through the recommendation of
876	the Compassionate Use Board under Section 26-61a-105.
877	(b) $[A]$ The recommending medical provider who made the underlying
878	recommendation for the card of a cardholder described in Subsection (6)(a) may renew the
879	cardholder's card[: (i) using the application process described in Subsection (3); or (ii)]
880	through phone or video conference with the [recommending medical provider who made the
881	recommendation underlying the card, at the qualifying] cardholder, at the recommending
882	medical provider's discretion.
883	(c) $[A]$ Before having access to a renewed card, a cardholder under Subsection (2)(a) or
884	(b) [who renews the cardholder's card] shall pay to the department a renewal fee in an amount
885	that:
886	(i) subject to Subsection 26-61a-109(5), the department sets in accordance with Section
887	63J-1-504; and
888	(ii) may not exceed the cost of the relatively lower administrative burden of renewal in
889	comparison to the original application process.
890	(d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
891	patient card renews automatically at the time the minor's parent or legal guardian renews the
892	parent or legal guardian's associated medical cannabis guardian card.
893	(7) (a) A cardholder under this section shall carry the cardholder's valid medical
894	cannabis card with the patient's name.
895	(b) (i) A medical cannabis patient cardholder or a provisional patient cardholder may

- purchase, in accordance with this chapter and the recommendation underlying the card,cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a
- 898 medical cannabis device.
- (ii) A cardholder under this section may possess or transport, in accordance with this
 chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a
 cannabis product in a medicinal dosage form, or a medical cannabis device.
- 902 (iii) To address the qualifying condition underlying the medical cannabis treatment903 recommendation:
- 904 (A) a medical cannabis patient cardholder or a provisional patient cardholder may use
 905 cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form,
 906 or a medical cannabis device; and
- 907 (B) a medical cannabis guardian cardholder may assist the associated provisional
 908 patient cardholder with the use of cannabis in a medicinal dosage form, a medical cannabis
 909 product in a medicinal dosage form, or a medical cannabis device.
- 910 (c) If a licensed medical cannabis pharmacy is not operating within the state after911 January 1, 2021, a cardholder under this section:
- 912 (i) may possess:
- 913 (A) up to the legal dosage limit of unprocessed cannabis in a medicinal dosage form;
- 914 (B) up to the legal dosage limit of a cannabis product in a medicinal dosage form; and
- 915 (C) marijuana drug paraphernalia; and
- 916 (ii) is not subject to prosecution for the possession described in Subsection (7)(c)(i).
- 917 (8) The department may revoke a medical cannabis card that the department issues918 under this section if the cardholder:
- 919 (a) violates this chapter; or
- 920 (b) is convicted under state or federal law of[: (i) a felony; or (ii)], after March 17,
- 921 2021, a [misdemeanor for] drug distribution offense.
- 922 (9) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
 923 Utah Administrative Rulemaking Act, a process to provide information regarding the following
- 924 to an individual receiving a medical cannabis card:
- 925 (a) risks associated with medical cannabis treatment;
- 926 (b) the fact that a condition's listing as a qualifying condition does not suggest that

927 medical cannabis treatment is an effective treatment or cure for that condition, as described in 928 Subsection 26-61a-104(1); and 929 (c) other relevant warnings and safety information that the department determines. 930 (10) The department may establish procedures by rule, in accordance with Title 63G, 931 Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance 932 provisions of this section. 933 (11) (a) On or before September 1, 2021, the department shall establish by rule, in 934 accordance with Title 63G. Chapter 3. Utah Administrative Rulemaking Act, a process to allow 935 an individual from another state to register with the department in order to purchase medical 936 cannabis or a medical cannabis device from a medical cannabis pharmacy while the individual 937 is visiting the state. 938 (b) The department may only provide the registration process described in Subsection 939 (11)(a): 940 (i) to a nonresident patient; and 941 (ii) for no more than two visitation periods per calendar year of up to 21 calendar days 942 per visitation period. 943 (12) (a) A person may submit to the department a request to conduct a research study 944 using medical cannabis cardholder data that the state electronic verification system contains. 945 (b) The department shall review a request described in Subsection (12)(a) to determine 946 whether an institutional review board, as that term is defined in Section 26-61-102, could 947 approve the research study. 948 (c) At the time an individual applies for a medical cannabis card, the department shall 949 notify the individual: 950 (i) of how the individual's information will be used as a cardholder; 951 (ii) that by applying for a medical cannabis card, unless the individual withdraws 952 consent under Subsection (12)(d), the individual consents to the use of the individual's 953 information for external research; and 954 (iii) that the individual may withdraw consent for the use of the individual's 955 information for external research at any time, including at the time of application. 956 (d) An applicant may, through the medical cannabis card application, and a medical 957 cannabis cardholder may, through the state central patient portal, withdraw the applicant's or

- 31 -

958 cardholder's consent to participate in external research at any time.

- (e) The department may release, for the purposes of a study described in this
 Subsection (12), information about a cardholder under this section who consents to participate
 under Subsection (12)(c).
- 962 (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of963 consent:
- 964 (i) applies to external research that is initiated after the withdrawal of consent; and
- 965 (ii) does not apply to research that was initiated before the withdrawal of consent.
- 966 (g) The department may establish standards for a medical research study's validity, by
 967 rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
- 968 (13) The department shall record the issuance or revocation of a medical cannabis card969 under this section in the controlled substance database.
- 970

Section 10. Section **26-61a-202** is amended to read:

971 **26-61a-202.** Medical cannabis caregiver card -- Registration -- Renewal --

972 **Revocation.**

- 973 (1) (a) (i) A cardholder described in Section 26-61a-201 may designate, through the
 974 state central patient portal, up to two individuals, or an individual and a facility in accordance
 975 with Subsection (1)(b), to serve as a designated caregiver for the cardholder.
- (ii) The designation described in Subsection (1)(a)(i) takes effect if the state electronic
 verification system reflects a recommending medical provider's indication that the provider
 determines that, due to physical difficulty or undue hardship, including concerns of distance to
 a medical cannabis pharmacy, the cardholder needs assistance to obtain the medical cannabis
 treatment that the recommending medical provider recommends.
- (b) (i) Beginning on the earlier of September 1, 2021, or the date on which the
 electronic verification system is functionally capable of servicing the designation, a cardholder
 described in Section 26-61a-201 [who is a patient in] may designate one of the following types
 of facilities may designate the facility as one of the caregivers described in Subsection (1)(a):
- 985 (A) for a patient or resident, an assisted living facility, as that term is defined in Section
 986 26-21-2;
- 987 (B) for a patient or resident, a nursing care facility, as that term is defined in Section
 988 26-21-2; [or]

989	(C) for a patient, a general acute hospital, as that term is defined in Section 26-21-2[-];
990	<u>or</u>
991	(D) for a student in a public school for which the principal has agreed to the
992	designation, the student's school.
993	(ii) A facility may:
994	(A) assign one or more employees to assist patients with medical cannabis treatment
995	under the caregiver designation described in this Subsection (1)(b)[-]; and
996	(B) receive a medical cannabis shipment from a medical cannabis pharmacy or a
997	medical cannabis courier on behalf of the medical cannabis cardholder within the facility who
998	designated the facility as a caregiver.
999	(iii) The department shall make rules to regulate the practice of facilities and facility
1000	employees serving as designated caregivers under this Subsection (1)(b).
1001	(c) A parent or legal guardian described in Subsection 26-61a-201(2)(d), in
1002	consultation with the minor and the minor's qualified medical provider, may designate, through
1003	the state central patient portal, up to two individuals to serve as a designated caregiver for the
1004	minor, if the department determines that the parent or legal guardian is not eligible for a
1005	medical cannabis guardian card under Section 26-61a-201.
1006	(d) A public school may not prohibit a student's dosage with medical cannabis or a
1007	medical cannabis product on the school grounds under the supervision of a medical cannabis
1008	guardian cardholder or a caregiver designated under this section.
1009	(2) An individual that the department registers as a designated caregiver under this
1010	section and a facility described in Subsection (1)(b):
1011	(a) for an individual designated caregiver, may carry a valid medical cannabis caregiver
1012	card;
1013	(b) in accordance with this chapter, may purchase, possess, transport, or assist the
1014	patient in the use of cannabis in a medicinal dosage form, a cannabis product in a medicinal
1015	dosage form, or a medical cannabis device on behalf of the designating medical cannabis
1016	cardholder;
1017	(c) may not charge a fee to an individual to act as the individual's designated caregiver
1018	or for a service that the designated caregiver provides in relation to the role as a designated
1019	caregiver;

1020	(d) may accept reimbursement from the designating medical cannabis cardholder for
1021	direct costs the designated caregiver incurs for assisting with the designating cardholder's
1022	medicinal use of cannabis; and
1023	(e) if a licensed medical cannabis pharmacy is not operating within the state after
1024	January 1, 2021:
1025	(i) may possess up to the legal dosage limit of:
1026	(A) unprocessed medical cannabis in a medicinal dosage form; and
1027	(B) a cannabis product in a medicinal dosage form;
1028	(ii) may possess marijuana drug paraphernalia; and
1029	(iii) is not subject to prosecution for the possession described in Subsection (2)(e)(i).
1030	(3) (a) The department shall:
1031	(i) within 15 days after the day on which an individual submits an application in
1032	compliance with this section, issue a medical cannabis card to the applicant if the applicant:
1033	(A) is designated as a caregiver under Subsection (1);
1034	(B) is eligible for a medical cannabis caregiver card under Subsection (4); and
1035	(C) complies with this section; and
1036	(ii) notify the Department of Public Safety of each individual that the department
1037	registers as a designated caregiver.
1038	(b) The department shall ensure that a medical cannabis caregiver card contains the
1039	information described in Subsection (5)(b).
1040	(4) An individual is eligible for a medical cannabis caregiver card if the individual:
1041	(a) is at least 21 years old;
1042	(b) is a Utah resident;
1043	(c) pays to the department a fee in an amount that, subject to Subsection
1044	26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the
1045	criminal background check described in Section 26-61a-203;
1046	(d) signs an acknowledgment stating that the applicant received the information
1047	described in Subsection 26-61a-201(9); and
1048	(e) has not been convicted of a misdemeanor or felony drug distribution offense that is
1049	a felony under either state or federal law, unless the individual completes any imposed sentence
1050	two or more years before the day on which the individual submits the application.

1051	(5) An eligible applicant for a medical cannabis caregiver card shall:
1052	(a) submit an application for a medical cannabis caregiver card to the department
1053	through an electronic application connected to the state electronic verification system; and
1054	(b) submit the following information in the application described in Subsection (5)(a):
1055	(i) the applicant's name, gender, age, and address;
1056	(ii) the name, gender, age, and address of the cardholder described in Section
1057	26-61a-201 who designated the applicant; and
1058	(iii) if a medical cannabis guardian cardholder designated the caregiver, the name,
1059	gender, and age of the minor receiving a medical cannabis treatment in relation to the medical
1060	cannabis guardian cardholder.
1061	(6) Except as provided in Subsection (6)(b), a medical cannabis caregiver card that the
1062	department issues under this section is valid for the lesser of:
1063	(a) an amount of time that the cardholder described in Section 26-61a-201 who
1064	designated the caregiver determines; or
1065	(b) the amount of time remaining before the card of the cardholder described in Section
1066	26-61a-201 expires.
1067	(7) (a) If a designated caregiver meets the requirements of Subsection (4), the
1068	designated caregiver's medical cannabis caregiver card renews automatically at the time the
1069	cardholder described in Section 26-61a-201 who designated the caregiver:
1070	(i) renews the cardholder's card; and
1071	(ii) renews the caregiver's designation, in accordance with Subsection (7)(b).
1072	(b) The department shall provide a method in the card renewal process to allow a
1073	cardholder described in Section 26-61a-201 who has designated a caregiver to:
1074	(i) signify that the cardholder renews the caregiver's designation;
1075	(ii) remove a caregiver's designation; or
1076	(iii) designate a new caregiver.
1077	(8) The department may revoke a medical cannabis caregiver card if the designated
1078	caregiver:
1079	(a) violates this chapter; or
1080	(b) is convicted under state or federal law of:
1081	(i) a felony drug distribution offense; or

1082 (ii) after December 3, 2018, a misdemeanor drug distribution offense. 1083 (9) The department shall record the issuance or revocation of a medical cannabis card 1084 under this section in the controlled substance database. 1085 Section 11. Section 26-61a-403 is amended to read: 1086 26-61a-403. Pharmacy medical providers -- Registration -- Continuing education. 1087 (1) (a) A medical cannabis pharmacy: 1088 (i) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy 1089 Practice Act, as a pharmacy medical provider; 1090 (ii) may employ a physician who has the authority to write a prescription and is 1091 licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah 1092 Osteopathic Medical Practice Act, as a pharmacy medical provider: 1093 (iii) shall ensure that a pharmacy medical provider described in Subsection (1)(a)(i)1094 works onsite during all business hours; and 1095 (iv) shall designate one pharmacy medical provider described in Subsection (1)(a)(i) as the pharmacist-in-charge to oversee the operation of and generally supervise the medical 1096 1097 cannabis pharmacy. 1098 (b) An individual may not serve as a pharmacy medical provider unless the department 1099 registers the individual as a pharmacy medical provider in accordance with Subsection (2). 1100 (2) (a) The department shall, within 15 days after the day on which the department 1101 receives an application from a medical cannabis pharmacy on behalf of a prospective pharmacy 1102 medical provider, register and issue a pharmacy medical provider registration card to the 1103 prospective pharmacy medical provider if the medical cannabis pharmacy: (i) provides to the department: 1104 1105 (A) the prospective pharmacy medical provider's name and address; 1106 (B) the name and location of the licensed medical cannabis pharmacy where the 1107 prospective pharmacy medical provider seeks to act as a pharmacy medical provider; 1108 (C) a report detailing the completion of the continuing education requirement described 1109 in Subsection (3); and 1110 (D) evidence that the prospective pharmacy medical provider is a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy Practice Act, or a physician who has the 1111 1112 authority to write a prescription and is licensed under Title 58, Chapter 67, Utah Medical

1113	Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and
1114	(ii) pays a fee to the department in an amount that, subject to Subsection
1115	26-61a-109(5), the department sets in accordance with Section 63J-1-504.
1116	(b) The department may not register a recommending medical provider or a state
1117	central patient portal medical provider as a pharmacy medical provider.
1118	(3) (a) A pharmacy medical provider shall complete the continuing education described
1119	in this Subsection (3) in the following amounts:
1120	(i) as a condition precedent to registration, four hours; and
1121	(ii) as a condition precedent to renewal of the registration, four hours every two years.
1122	(b) In accordance with Subsection (3)(a), the pharmacy medical provider shall:
1123	(i) complete continuing education:
1124	(A) regarding the topics described in Subsection (3)(d); and
1125	(B) offered by the department under Subsection (3)(c) or an accredited or approved
1126	continuing education provider that the department recognizes as offering continuing education
1127	appropriate for the medical cannabis pharmacy practice; and
1128	(ii) make a continuing education report to the department in accordance with a process
1129	that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah
1130	Administrative Rulemaking Act, and in collaboration with the Division of Occupational and
1131	Professional Licensing and:
1132	(A) for a pharmacy medical provider who is licensed under Title 58, Chapter 17b,
1133	Pharmacy Practice Act, the Board of Pharmacy;
1134	(B) for a pharmacy medical provider licensed under Title 58, Chapter 67, Utah Medical
1135	Practice Act, the Physicians Licensing Board; and
1136	(C) for a pharmacy medical provider licensed under Title 58, Chapter 68, Utah
1137	Osteopathic Medical Practice Act, the Osteopathic Physician and Surgeon's Licensing Board.
1138	(c) The department may, in consultation with the Division of Occupational and
1139	Professional Licensing, develop the continuing education described in this Subsection (3).
1140	(d) The continuing education described in this Subsection (3) may discuss:
1141	(i) the provisions of this chapter;
1142	(ii) general information about medical cannabis under federal and state law;
1143	(iii) the latest scientific research on the endocannabinoid system and medical cannabis,

1144	including risks and benefits;
1145	(iv) recommendations for medical cannabis as it relates to the continuing care of a
1146	patient in pain management, risk management, potential addiction, and palliative care; or
1147	(v) best practices for recommending the form and dosage of a medical cannabis
1148	product based on the qualifying condition underlying a medical cannabis recommendation.
1149	(4) (a) A pharmacy medical provider registration card expires two years after the day
1150	on which the department issues or renews the card.
1151	(b) A pharmacy medical provider may renew the provider's registration card if the
1152	provider:
1153	(i) is eligible for a pharmacy medical provider registration card under this section;
1154	(ii) certifies to the department in a renewal application that the information in
1155	Subsection (2)(a) is accurate or updates the information;
1156	(iii) submits a report detailing the completion of the continuing education requirement
1157	described in Subsection (3); and
1158	(iv) pays to the department a renewal fee in an amount that:
1159	(A) subject to Subsection $26-61a-109(5)$, the department sets in accordance with
1160	Section 63J-1-504; and
1161	(B) may not exceed the cost of the relatively lower administrative burden of renewal in
1162	comparison to the original application process.
1163	(5) (a) Except as provided in Subsection (5)(b), [an individual] a person may not
1164	advertise that the [individual] person or another person dispenses medical cannabis.
1165	(b) [For purposes of this] Notwithstanding Subsection (5)(a)[, the communication of
1166	the following, through a website, by a pharmacy medical provider, does not constitute
1167	advertising] and subject to Section 26-61a-116, a registered pharmacy medical provider may
1168	advertise the following:
1169	(i) a green cross;
1170	(ii) [the individual's registration] that the person is registered as a pharmacy medical
1171	provider and dispenses medical cannabis; or
1172	(iii) a scientific study regarding medical cannabis use.
1173	Section 12. Section 26-61a-505 is amended to read:
1174	26-61a-505. Medical cannabis pharmacy advertising.

1175	(1) Except as provided in this section, a [medical cannabis pharmacy] person may not
1176	advertise in any medium regarding a medical cannabis pharmacy or the dispensing of medical
1177	cannabis within the state.
1178	(2) [A] Subject to Section 26-61a-116, a medical cannabis pharmacy may:
1179	(a) advertise an employment opportunity at the medical cannabis pharmacy[-;];
1180	[(3) (a) Notwithstanding]
1181	(b) notwithstanding any municipal or county ordinance prohibiting signage, [a medical
1182	cannabis pharmacy may] use signage on the outside of the medical cannabis pharmacy that:
1183	(i) includes only:
1184	(A) in accordance with Subsection $[(3)](2)(b)$, the medical cannabis pharmacy's name,
1185	logo, and hours of operation; and
1186	(B) a green cross; and
1187	(ii) complies with local ordinances regulating signage[-];
1188	[(b) The department shall define standards for a medical cannabis pharmacy's name
1189	and logo to ensure a medical rather than recreational disposition.]
1190	[(4) (a) A medical cannabis pharmacy may]
1191	(c) maintain a website that includes information about:
1192	(i) the location and hours of operation of the medical cannabis pharmacy;
1193	(ii) a product or service available at the medical cannabis pharmacy;
1194	(iii) personnel affiliated with the medical cannabis pharmacy;
1195	(iv) whether the medical cannabis pharmacy is licensed as a home delivery medical
1196	cannabis pharmacy;
1197	[(iv)] (v) best practices that the medical cannabis pharmacy upholds; and
1198	[(v)] (vi) educational material related to the medical use of cannabis, as defined by the
1199	department[-]; and
1200	(d) hold an educational event for the public or medical providers in accordance with
1201	Subsection (3) and the rules described in Subsection (4).
1202	[(b) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1203	Administrative Rulemaking Act, to define the educational material described in Subsection
1204	(4)(a).]
1205	[(5) (a) A medical cannabis pharmacy may hold an educational event for the public or

1206	medical providers in accordance with this Subsection (5) and the rules described in Subsection
1207	(5)(c).]
1208	[(b)] (3) A medical cannabis pharmacy may not include in an educational event
1209	described in Subsection [(5)(a)] (2)(d):
1210	[(i)] (a) any topic that conflicts with this chapter or Title 4, Chapter 41a, Cannabis
1211	Production Establishments;
1212	[(ii)] (b) any gift items or merchandise other than educational materials, as those terms
1213	are defined by the department;
1214	[(iii)] (c) any marketing for a specific product from the medical cannabis pharmacy or
1215	any other statement, claim, or information that would violate the federal Food, Drug, and
1216	Cosmetic Act, 21 U.S.C. Sec. 301, et seq.; or
1217	[(iv)] (d) a presenter other than the following:
1218	[(A)] (i) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
1219	[(B)] (ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b,
1220	Nurse Practice Act;
1221	[(C)] (iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act,
1222	or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act;
1223	[(D)] (iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1224	Assistant Act;
1225	[(E)] (v) a medical practitioner, similar to the practitioners described in this Subsection
1226	[(5)(b)(iv)] (3)(d)(v), who is licensed in another state or country;
1227	[(F)] <u>(vi)</u> a state employee; or
1228	[(G)] (vii) if the presentation relates to a cannabis topic other than medical treatment or
1229	medical conditions, an individual whom the department approves based on the individual's
1230	background and credentials in the presented topic.
1231	[(c)] (4) The department shall make rules, in accordance with Title 63G, Chapter 3,
1232	Utah Administrative Rulemaking Act, to define:
1233	(a) the educational material described in Subsection (2)(c)(v); and
1234	(b) the elements of and restrictions on the educational event described in Subsection
1235	[(5)(a),] <u>(3)</u> including:
1236	(i) a minimum age of 21 years old for attendees; and

1237	(ii) an exception to the minimum age for a medical cannabis patient cardholder who is
1238	at least 18 years old.
1239	Section 13. Section 26-61a-604 is amended to read:
1240	26-61a-604. Home delivery of medical cannabis shipments Medical cannabis
1241	couriers License.
1242	(1) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1243	Administrative Rulemaking Act, to ensure the safety, security, and efficiency of a home
1244	delivery medical cannabis pharmacy's fulfillment of electronic medical cannabis orders that the
1245	state central patient portal facilitates, including rules regarding the safe and controlled delivery
1246	of medical cannabis shipments.
1247	(2) A person may not operate as a medical cannabis courier without a license that the
1248	department issues under this section.
1249	(3) (a) Subject to Subsections (5) and (6), the department shall issue a license to
1250	operate as a medical cannabis courier to an applicant who is eligible for a license under this
1251	section.
1252	(b) An applicant is eligible for a license under this section if the applicant submits to
1253	the department:
1254	(i) the name and address of an individual who:
1255	(A) has a financial or voting interest of 2% or greater in the proposed medical cannabis
1256	pharmacy; or
1257	(B) has the power to direct or cause the management or control of a proposed cannabis
1258	production establishment;
1259	(ii) an operating plan that includes operating procedures to comply with the operating
1260	requirements for a medical cannabis courier described in this chapter; and
1261	(iii) an application fee in an amount that, subject to Subsection 26-61a-109(5), the
1262	department sets in accordance with Section 63J-1-504.
1263	(4) If the department determines that an applicant is eligible for a license under this
1264	section, the department shall:
1265	(a) charge the applicant an initial license fee in an amount that, subject to Subsection
1266	26-61a-109(5), the department sets in accordance with Section 63J-1-504; and
1267	(b) notify the Department of Public Safety of the license approval and the names of

S.B. 195

1268	each individual described in Subsection (3)(b)(ii).
1269	(5) The department may not issue a license to operate as a medical cannabis courier to
1270	an applicant if an individual described in Subsection (3)(b)(ii):
1271	(a) has been convicted under state or federal law of:
1272	(i) a felony; or
1273	(ii) after September 23, 2019, a misdemeanor for drug distribution; or
1274	(b) is younger than 21 years old.
1275	(6) The department may revoke a license under this part if:
1276	(a) the medical cannabis courier does not begin operations within one year after the day
1277	on which the department issues the initial license;
1278	(b) the medical cannabis courier makes the same violation of this chapter three times;
1279	or
1280	(c) an individual described in Subsection (3)(b)(ii) is convicted, while the license is
1281	active, under state or federal law of:
1282	(i) a felony; or
1283	(ii) after September 23, 2019, a misdemeanor for drug distribution.
1284	(7) The department shall deposit the proceeds of a fee imposed by this section in the
1285	Qualified Patient Enterprise Fund.
1286	(8) The department shall begin accepting applications under this section on or before
1287	July 1, 2020.
1288	(9) The department's authority to issue a license under this section is plenary and is not
1289	subject to review.
1290	(10) Each applicant for a license as a medical cannabis courier shall submit, at the time
1291	of application, from each individual who has a financial or voting interest of 2% or greater in
1292	the applicant or who has the power to direct or cause the management or control of the
1293	applicant:
1294	(a) a fingerprint card in a form acceptable to the Department of Public Safety;
1295	(b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
1296	registration of the individual's fingerprints in the Federal Bureau of Investigation Next
1297	Generation Identification System's Rap Back Service; and
1298	(c) consent to a fingerprint background check by:

1299	(i) the Bureau of Criminal Identification; and
1300	(ii) the Federal Bureau of Investigation.
1301	(11) The Bureau of Criminal Identification shall:
1302	(a) check the fingerprints the applicant submits under Subsection (10) against the
1303	applicable state, regional, and national criminal records databases, including the Federal
1304	Bureau of Investigation Next Generation Identification System;
1305	(b) report the results of the background check to the department;
1306	(c) maintain a separate file of fingerprints that applicants submit under Subsection (10)
1307	for search by future submissions to the local and regional criminal records databases, including
1308	latent prints;
1309	(d) request that the fingerprints be retained in the Federal Bureau of Investigation Next
1310	Generation Identification System's Rap Back Service for search by future submissions to
1311	national criminal records databases, including the Next Generation Identification System and
1312	latent prints; and
1313	(e) establish a privacy risk mitigation strategy to ensure that the department only
1314	receives notifications for an individual with whom the department maintains an authorizing
1315	relationship.
1316	(12) The department shall:
1317	(a) assess an individual who submits fingerprints under Subsection (10) a fee in an
1318	amount that the department sets in accordance with Section 63J-1-504 for the services that the
1319	Bureau of Criminal Identification or another authorized agency provides under this section; and
1320	(b) remit the fee described in Subsection (12)(a) to the Bureau of Criminal
1321	Identification.
1322	(13) The department shall renew a license under this section every year if, at the time
1323	of renewal:
1324	(a) the licensee meets the requirements of this section; and
1325	(b) the licensee pays the department a license renewal fee in an amount that, subject to
1326	Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504.
1327	(14) A person applying for a medical cannabis courier license shall submit to the
1328	department a proposed operating plan that complies with this section and that includes:
1329	(a) a description of the physical characteristics of any proposed facilities, including a

S.B. 195

1330	floor plan and an architectural elevation, and delivery vehicles;
1331	(b) a description of the credentials and experience of each officer, director, or owner of
1332	the proposed medical cannabis courier;
1333	(c) the medical cannabis courier's employee training standards;
1334	(d) a security plan; and
1335	(e) storage and delivery protocols, both short and long term, to ensure that medical
1336	cannabis shipments are stored and delivered in a manner that is sanitary and preserves the
1337	integrity of the cannabis.
1338	(15) (a) Except as provided in Subsection (15)(b), a person may not advertise regarding
1339	the transportation of medical cannabis.
1340	(b) Notwithstanding Subsection (15)(a) and subject to Section 26-61a-116, a licensed
1341	home delivery medical cannabis pharmacy or a licensed medical cannabis courier may
1342	advertise:
1343	(i) a green cross; and
1344	(ii) that the pharmacy or courier is licensed to transport medical cannabis shipments.
1345	Section 14. Section 26-61a-607 is amended to read:
1346	26-61a-607. Home delivery of medical cannabis shipments.
1347	(1) An individual may not receive and a medical cannabis pharmacy agent or a medical
1348	cannabis courier agent may not deliver a medical cannabis shipment from a home delivery
1349	medical cannabis pharmacy unless:
1350	(a) the individual receiving the shipment presents:
1351	(i) a valid form of photo identification; and
1352	(ii) (A) a valid medical cannabis card under the same name that appears on the valid
1353	form of photo identification; [and] or
1354	(B) for a facility that a medical cannabis cardholder has designated as a caregiver under
1355	Subsection 26-61a-202(1)(b), evidence of the facility caregiver designation; and
1356	(b) the delivery occurs at:
1357	(i) the medical cannabis cardholder's home address that is on file in the state electronic
1358	verification system[-]; or
1359	(ii) the facility that the medical cannabis cardholder has designated as a caregiver under
1360	Subsection 26-61a-202(1)(b).

1361	(2) Before a medical cannabis pharmacy agent or a medical cannabis courier agent
1362	distributes a medical cannabis shipment to a medical cannabis cardholder, the agent shall:
1363	(a) verify the shipment information using the state electronic verification system;
1364	(b) ensure that the individual satisfies the identification requirements in Subsection (1);
1365	(c) verify that payment is complete; and
1366	(d) record the completion of the shipment transaction in a manner such that the
1367	delivery of the shipment will later be recorded within a reasonable period in the electronic
1368	verification system.
1369	(3) The medical cannabis courier shall:
1370	(a) (i) store each medical cannabis shipment in a secure manner until the recipient
1371	medical cannabis cardholder receives the shipment or the medical cannabis courier returns the
1372	shipment to the home delivery medical cannabis pharmacy in accordance with Subsection (4);
1373	and
1374	(ii) ensure that only a medical cannabis courier agent is able to access the medical
1375	cannabis shipment until the recipient medical cannabis cardholder receives the shipment;
1376	(b) return any undelivered medical cannabis shipment to the home delivery medical
1377	cannabis pharmacy, in accordance with Subsection (4), after the medical cannabis courier has
1378	possessed the shipment for 10 business days; and
1379	(c) return any medical cannabis shipment to the home delivery medical cannabis
1380	pharmacy, in accordance with Subsection (4), if a medical cannabis cardholder refuses to
1381	accept the shipment.
1382	(4) (a) If a medical cannabis courier or home delivery medical cannabis pharmacy
1383	agent returns an undelivered medical cannabis shipment that remains unopened, the home
1384	delivery medical cannabis pharmacy may repackage or otherwise reuse the shipment.
1385	(b) If a medical cannabis courier or home delivery medical cannabis pharmacy agent
1386	returns an undelivered or refused medical cannabis shipment under Subsection (3) that appears
1387	to be opened in any way, the home delivery medical cannabis pharmacy shall dispose of the
1388	shipment by:
1389	(i) rendering the shipment unusable and unrecognizable before transporting the
1390	shipment from the home delivery medical cannabis pharmacy; and
1391	(ii) disposing of the shipment in accordance with:

1392	(A) federal and state laws, rules, and regulations related to hazardous waste;
1393	(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
1394	(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
1395	(D) other regulations that the department makes in accordance with Title 63G, Chapter
1396	3, Utah Administrative Rulemaking Act.
1397	Section 15. Section 26-61a-702 is amended to read:
1398	26-61a-702. Enforcement Fine Citation.
1399	(1) (a) The department may, for a medical cannabis pharmacy's or a medical cannabis
1400	courier's violation of this chapter or an applicable administrative rule:
1401	(i) revoke the medical cannabis pharmacy or medical cannabis courier license;
1402	(ii) refuse to renew the medical cannabis pharmacy or medical cannabis courier
1403	license; or
1404	(iii) assess the medical cannabis pharmacy or medical cannabis courier an
1405	administrative penalty.
1406	(b) The department may, for a medical cannabis pharmacy agent's or medical cannabis
1407	courier agent's violation of this chapter:
1408	(i) revoke the medical cannabis pharmacy agent or medical cannabis courier agent
1409	registration card;
1410	(ii) refuse to renew the medical cannabis pharmacy agent or medical cannabis courier
1411	agent registration card; or
1412	(iii) assess the medical cannabis pharmacy agent or medical cannabis courier agent an
1413	administrative penalty.
1414	(2) The department shall deposit an administrative penalty imposed under this section
1415	into the General Fund.
1416	(3) For a person subject to an uncontested citation, a stipulated settlement, or a finding
1417	of a violation in an adjudicative proceeding under this section, the department may:
1418	(a) for a fine amount not already specified in law, assess the person a fine of up to
1419	\$5,000 per violation, in accordance with a fine schedule that the department establishes by rule
1420	in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act; or
1421	(b) order the person to cease and desist from the action that creates a violation.
1422	(4) The department may not revoke a medical cannabis pharmacy's license or a medical

1423	cannabis courier's license without first directing the medical cannabis pharmacy or the medical
1424	cannabis courier to appear before an adjudicative proceeding conducted under Title 63G,
1425	Chapter 4, Administrative Procedures Act.
1426	(5) If, within 20 calendar days after the day on which the department issues a citation
1427	for a violation of this chapter, the person that is the subject of the citation fails to request a
1428	hearing to contest the citation, the citation becomes the department's final order.
1429	(6) The department may, for a person who fails to comply with a citation under this
1430	section:
1431	(a) refuse to issue or renew the person's license or agent registration card; or
1432	(b) suspend, revoke, or place on probation the person's license or agent registration
1433	card.
1434	(7) (a) Except where a criminal penalty is expressly provided for a specific violation of
1435	this chapter, if an individual violates a provision of this chapter, the individual is:
1436	(i) guilty of an infraction; and
1437	(ii) subject to a \$100 fine.
1438	(b) An individual who is guilty of a violation described in Subsection (7)(a) is not
1439	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
1440	underlying the violation described in Subsection (7)(a).
1441	Section 16. Section 53B-17-903 is enacted to read:
1442	53B-17-903. Education in pain treatment.
1443	The University of Utah School of Medicine shall ensure that any licensed physicians
1444	who oversee fellowship training to specialize in pain treatment are qualified medical providers,
1445	as that term is defined in Section 26-61a-102.
1446	Section 17. Effective date.
1447	If approved by two-thirds of all the members elected to each house, this bill takes effect
1448	upon approval by the governor, or the day following the constitutional time limit of Utah
1449	Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,

1450 <u>the date of veto override.</u>